Table 1.
Antimicrobial activity (MIC [μM]), toxicity [μM] and haemolytic properties for Pt1‐14 and Pd1 determined in the CO‐ADD screening.
|
|
Sa[a] |
Ec[b] |
Kp[c] |
Pa[d] |
Ab[e] |
Ca[f] |
Cn[g] |
HEK‐293 CC50 |
Haemolysis |
|
|---|---|---|---|---|---|---|---|---|---|---|
|
HC10 |
HC50 |
|||||||||
|
Pt1 |
0.625–2.5 |
>20 |
>20 |
>20 |
>20 |
10–20 |
1.25–5 |
>100 |
>100 |
>100 |
|
Pt2 |
1.25 |
>20 |
>20 |
>20 |
>20 |
10 |
2.5 |
>100 |
>100 |
>100 |
|
Pt3 |
n.d. |
n.d. |
n.d. |
n.d. |
n.d. |
n.d. |
n.d. |
>100 |
>100 |
>100 |
|
Pt4 |
>20 |
>20 |
>20 |
>20 |
>20 |
5–10 |
10–20 |
>100 |
10.23 |
52.11 |
|
Pt5 |
>20 |
>20 |
>20 |
>20 |
>20 |
10 |
20 |
>100 |
88.43 |
>100 |
|
Pt6 |
10 |
>20 |
>20 |
>20 |
>20 |
20 |
20 |
>100 |
>100 |
>100 |
|
Pt7 |
>20 |
>20 |
>20 |
>20 |
>20 |
10 |
20 |
>100 |
10.27 |
52.12 |
|
Pt8 |
>20 |
>20 |
>20 |
>20 |
>20 |
10 |
1.25 |
>100 |
>100 |
>100 |
|
Pt9 |
>20 |
>20 |
>20 |
>20 |
>20 |
>20 |
1.25 |
>100 |
>100 |
>100 |
|
Pd1 |
n.d. |
n.d. |
n.d. |
n.d. |
n.d. |
n.d. |
n.d. |
>100 |
7.76 |
10.14 |
|
Pt10‐14 |
>20 |
>20 |
>20 |
>20 |
>20 |
– |
– |
– |
– |
– |
|
Colistinh |
|
0.125 |
0.25 |
0.25 |
0.25 |
|
|
|
|
|
|
Vancomycinh |
1 |
|
|
|
|
|
|
|
|
|
|
Tamoxifen |
|
|
|
|
|
|
|
34.75–30.55 |
|
|
|
Melittin |
|
|
|
|
|
|
|
|
1.15 |
1.82 |
[a] Sa – Staphylococcus aureus ATCC 43300 (MRSA); [b] Ec – Escherichia coli ATCC 25922; [c] Kp – Klebsiella pneumoniae ATCC 700603 (ESBL SHV‐18); [d] Pa – Pseudomonas aeruginosa ATCC 27853; [e] Ab – Acinetobacter baumannii ATCC 19606; [f] Ca – Candida albicans ATCC 90028; [g] Cn – Cryptococcus neoformans H99 ATCC 208821; [h] MIC for Colistin and Vancomycin given in μg/mL. MIC – Minimum Inhibitory Concentration; CC50 – concentration causing 50 % cytotoxicity; HC10, HC50 – concentration inducing 10 % or 50 % haemolysis, respectively.